From the American Journal of Clinical Nutrition (April 22, 2020):
Our findings imply that higher long-term dietary intakes of flavonoids are associated with lower risks of ADRD and AD in US adults.
Our findings provide new evidence that diets higher in flavonols, anthocyanins, and flavonoid polymers are associated with a lower risk of developing ADRD. These associations were sustained after accounting for a variety of potential confounders including key nutrients related to ADRD risk and overall diet quality. Similar findings were seen with AD risk for flavonols and anthocyanins but the association with flavonoid polymers was no longer statistically significant.
Along with improvements in healthcare and medical technology, the aging of the baby boom generation will result in an unprecedented rise in the number of older Americans (1, 2). Currently, there are >50 million Americans aged ≥65 y, and that is projected to more than double by 2060 (3). A consequence of this increase in older adults is the escalation of age-related diseases (4, 5). Alzheimer disease (AD) and related dementias (ADRD), a group of symptoms in which there is progressive deterioration in cognitive function severe enough to interfere with a person’s daily living activities, are regarded as among the most significant public health challenges largely affecting adults aged >65 y (6). AD is the most common form of dementia, making up ∼60–80% of dementia cases. Currently, 5.8 million Americans are living with AD, and by 2050 that is projected to escalate to 14 million (7).
An estimated 80 million people live with a neurodegenerative disease, with this number expected to double by 2050. Despite decades of research and billions in funding, there are no medications that can slow, much less stop, the progress of these diseases. The time to rethink degenerative brain disorders has come. With no biological boundaries between neurodegenerative diseases, illnesses such as Parkinson’s and Alzheimer’s result from a large spectrum of biological abnormalities, hampering effective treatment.
Acclaimed neurologist Dr Alberto Espay and Parkinson’s advocate Benjamin Stecher present compelling evidence that these diseases should be targeted according to genetic and molecular signatures rather than clinical diagnoses. There is no Parkinson’s or Alzheimer’s, simply people with Parkinson’s or Alzheimer’s. An incredibly important story never before told, Brain Fables is a wakeup call to the scientific community and society, explaining why we have no effective disease-modifying treatments, and how we can get back on track.
From a Rush University Medical Center online article:
The study found that participants in the group with the highest flavonol consumption were 48% less likely to develop Alzheimer’s dementia later on in life than participants with the lowest level. Of the 186 people in the highest group, 28 people, or 15%, developed Alzheimer’s dementia, compared to 54 people, or 30%, of the 182 people in the lowest group.
People who eat or drink more foods with flavonol, which is found in nearly all fruits and vegetables, plus tea and wine, may be less likely to develop Alzheimer’s dementia, according to the Rush researchers. They published the results of their study in the Jan. 29 online issue of Neurology.
Flavonols are a type of flavonoid, a group of phytochemicals found in plant pigments. They are known for their beneficial effects on health due to their antioxidant and anti-inflammatory properties.
A total of 921 people with an average age of 81 participated in the Neurology study. These participants did not have Alzheimer’s dementia when starting the study.
“Amyloid is important in initiating disease, but the actual damage in the brain is probably due to the accumulation of tau,” Holtzman told MedPage Today. “Normally, tau protein is inside cells, but there is more and more evidence suggesting that its spread to different parts of the brain is responsible for the progression of Alzheimer’s disease.”
Two studies in January explored how sleep might be associated with Alzheimer’s tau pathology. The first, led by Brendan Lucey, MD, and David Holtzman, MD, both of Washington University in St. Louis, found that older adults who had less slow-wave sleep had higher levels of brain tau.
Dr. Nilüfer Ertekin-Taner, neurogeneticist and behavioral neurologist, discusses characteristics of neurodegenerative diseases such as dementia, Alzheimer’s disease, and movement disorders. She also discusses her research on the complex genetics of Alzheimer’s disease, including identifying therapeutic targets and biomarkers. She highlights Mayo Clinic’s unique approach to patient care.
Mr. Chambers, a 48-year-old physical therapist in Jersey City, N.J., modified his sleep, diet and exercise routines. Eighteen months later, his performance on a battery of cognitive tests improved, particularly in areas like processing speed and executive function, such as decision-making and planning.
Most surprising, says Dr. Isaacson, is that the MCI patients who followed at least 60% of their recommendations showed cognitive improvement. However, MCI patients who followed less than 60% of the recommendations experienced cognitive declines similar to the control groups, he notes.
Mr. Chambers is among 154 patients in a study, published Wednesday in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, that doctors say shows encouraging results. Among healthy patients, people who made changes in nutrition and exercise showed cognitive improvements on average. People who were already experiencing some memory problems also showed cognitive improvement—if they followed at least 60% of the recommended changes.
At the core of the 2019 report are the results of a global survey, commissioned by ADI and undertaken by the London School of Economics and Political Science (LSE). Almost 70,000 people globally engaged with the survey, making it the biggest of its kind ever undertaken.
LSE developed the survey to target four key groups:
(1) people living with dementia, (2) careers, (3) healthcare practitioners and (4) the general public, with analysis being provided in three categories: knowledge, attitudes and behaviour.
In the survey analysis we highlight the behavioural element first, giving prominence to the voices and experiences of people living with dementia as direct assessment of actual behaviour is central to discrimination and is the closest representation of the true impact of stigma on people living with dementia.